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Multi-morbidity and polypharmacy are common among older people. It is essential to provide a 31 
better understanding of the complexity of prescription drug use among older adults to optimise 32 
rational pharmacotherapy. Population-based utilisation data in this age group is limited. Using the 33 
Danish nationwide health registries, we aimed to characterise drug use among Danish individuals 34 
≥60 years.  35 
Methods 36 
This is a descriptive population-based study assessing drug prescription patterns in 2015 in the full 37 
Danish population aged ≥60 years. The use of specific therapeutic subgroups and chemical 38 
subgroups and its dependence on age were described using descriptive statistics. Profiles of drug 39 
combination patterns were evaluated using latent class analysis.  40 
Results 41 
We included 1,424,775 residents (median age 70 years, 53% women). Of all the older adults, 89% 42 
filled at least one prescription during 2015. The median number of drug groups used was five per 43 
person. The most used single drug groups were anilides (34%), statins (33%), and platelet 44 
aggregation inhibitors (24%). Eighteen drug profiles with different drug combination patterns were 45 
identified. One drug profile with expected use of zero drugs and 11 drug profiles expected to receive 46 
more than five different therapeutic subgroup drugs were identified.  47 
Conclusion 48 
The use of drugs is extensive both at the population level and increasing with age at an individual 49 
level. Separating the population into different homogenous groups related to drug use resulted in 18 50 
different drug profiles of which 11 drug profiles received on average more than five different 51 
therapeutic subgroup drugs. 52 
  53 
  
What is already known about this subject 54 
• The use of prescription drugs is common in older people  55 
• The use of many drugs simultaneously increases the risk of adverse drug events and drug-56 
drug interactions 57 
 58 
What this study adds 59 
• A better and updated understanding of the real-life utilisation of prescription drugs among 60 
older adults ≥60 years  61 
• An understanding of how drugs tend to compound 62 
• Drug profiles with clinical recognisable medication profiles for the entire older population  63 
  64 
  
Introduction 65 
The use of prescription drugs is widespread in older people1,2, and the number of drugs used is 66 
increasing with age 3–6. This is prompted by an increasing prevalence of multi-morbidity and 67 
hospitalisations by age supplemented by a higher number of specialists who treat single diseases7–9. 68 
Strict adherence to guidelines for each of the chronic conditions may complicate older persons’ 69 
pharmacotherapy and may be associated with adverse drug events10. Furthermore, the use of many 70 
drugs simultaneously increases the risk of adverse drug events and drug-drug interactions11,12. Due to 71 
age-related changes in pharmacokinetics and pharmacodynamics, older people are at very high risk of 72 
such complications1,5,11,13. To this end, up to 30% of hospital admissions in older patients are related to 73 
adverse drug events14–16. Thus, pharmacotherapy in the older adults is very complicated, and the vast 74 
variety of drugs and drug combinations effect on the pharmacokinetics and pharmacodynamics and 75 
makes it a difficult phenomenon to analyse.  76 
 77 
A better and updated understanding of the real-life utilisation of prescription drugs is needed, and 78 
further research is required to deepen our understanding of how drugs tend to compound and 79 
interact. In addition, identifying common drug profiles, i.e. which drugs are used together, to 80 
identify long-term risk drug profiles may enable health care policies, clinicians, and research fellows 81 
to optimise a rational pharmacotherapy, prescribing and deprescribing patterns among older adults. 82 
However, the population-based utilisation data in this age group is limited, and data are rather old. 83 
Therefore, we aimed to provide a detailed study of drug use and how it changes with age to identify 84 
different homogeneous drug profiles among older adults aged 60 years and older. 85 
 86 
Methods 87 
We performed a nationwide cross-sectional drug utilisation study in the older adult Danish population.  88 
 89 
Data sources 90 
Denmark has a public tax-financed health care system, which provides free and equal access 91 
to primary medical care, hospitals, and home care services for all people. Patient co-payments are 92 
required for prescription drugs. A central authority (the Reimbursement Committee) decides 93 
whether a particular drug is reimbursable. Some prescription drugs, e.g. benzodiazepines are not 94 
reimbursed17. Virtually all medical care in Denmark is furnished by the public health authorities, 95 
whereby the data resources allow accurate population-based studies, covering all inhabitants of 96 
Denmark.  97 
  
 98 
We used data from five Danish nationwide registries; the National Prescription Registry, the Danish 99 
Education Registry, the Registry for Migration, the Danish Registry of Causes of Death, and the 100 
Civil Registration System. The National Prescription Registry contains full information on all 101 
prescription drugs dispensed at Danish community pharmacies including prescriptions for nursing 102 
home residents17. Prescriptions are coded according to the Anatomical Therapeutic Chemical (ATC) 103 
classification system18. Drugs used during hospitalisation are not recorded in the register. The 104 
Danish Education Register contains information on ongoing and completed education19. The 105 
Register for Migration contains the date of both immigration and emigration20. The Danish Register 106 
of Causes of Death contains data on all deaths among people dying in Denmark21. The Civil 107 
Registration System contains various information including sex, date of birth, and updated 108 
information on vital status22. All Danish residents are recorded in the registries with a uniquely 109 
personal and permanent identification number that makes it possible to crosslink individual-level 110 
data across the different registries. 111 
 112 
Study population  113 
We included all Danish residents aged≥60 years on January 1 2016. Residents who migrated during 114 
2015 were excluded to ensure full follow-up data on all subjects.  115 
 116 
Study variables  117 
Study drugs 118 
We retrieved information on all redeemed prescriptions in 2015. The drugs were categorised 119 
according to ATC-codes into the anatomical main group (1st level), therapeutic subgroup (2nd level), 120 
and chemical subgroup (4th level)18. ATC Level 1, 2, and 4 are referred to as main drug group, 121 
therapeutic subgroup drug, and drug class, respectively. We defined drug users as individuals who 122 
had redeemed at least one prescription of a drug class or main drug group in 2015. In the latent class 123 
analysis (LCA), we disregarded the main drug group: anti-infectives for systemic use. 124 
 125 
Sociodemographic factors 126 
The marital status was categorised according to status on January 1 ,2016, as: married, widowed, 127 
divorced or single, whereas education was categorised according to the highest attained educational 128 
level at January 1 2016: short (7-10 years), medium (11-13 years) or long (≥14 years). 129 
 130 
  
2.4 Analyses  131 
First, we described baseline characteristics, i.e. sex, marital status, and education of the study 132 
population. To investigate simultaneous drug use, we measured the proportion of users of 0, 1-2, 3-133 
4, 5-9, or 10+ different drug classes in 2015 stratified by age groups. Second, we determined the ten 134 
most frequently used drugs classes stratified by age groups. Third, we reported the number of 135 
redeemed drug classes among all residents as mean, median, interquartile range, minimum, and 136 
maximum, stratified by 1-year age categories. Finally, we identified the number of residents who 137 
filled at least one prescription of a main drug group in 2015. These analyses were stratified by 1-year 138 
age categories.  139 
 140 
Finally, we identified drug profiles using LCA. LCA is a method designed to identify subgroups of 141 
residents who show similar patterns of behaviour, e.g. drug use23. LCA classifies individuals into 142 
mutually exclusive latent classes and assumes that given the latent class membership the use of drugs 143 
is independent; thus, we used the LCA to identify different drug patterns in the general older adult 144 
population. Each class identified in the LCA will thus have similar drug patterns and therefore have 145 
the same drug profile. To reduced computer running time we selected five random samples of our 146 
population, each with 50,000 residents. For the same reason, we chose drugs at therapeutic 147 
subgroup level instead of drug classes. To avoid too few observation, the drugs were identified as 148 
the 95% most used drugs in 2015. Thus, the LCA was based on drugs from 28 therapeutic 149 
subgroups. Moreover, this made it possible to investigate the consistency of the drug profiles 150 
identified in five random samples. The number of drug profiles was estimated in an iterative process 151 
starting with a model with a two LCA class solution and continuing up to 20 LCA classes for each 152 
of the five datasets. To measure the relative fit of the models, which refers to the adequacy of one 153 
model’s representation of data compared with that of another model, we used the Bayesian 154 
Information Criterion (BIC)24. This was used together with substantive interpretability and clinical 155 
judgment to determine the number of drug profiles for each of the five datasets25. Afterwards, the 156 
optimal number of drug profiles and parameter estimates were compared for the five datasets, and 157 
the final number of drug profiles was decided. The entropy-based pseudo-R2 measure can 158 
summarise the association between the drug profiles. The values 0.36, 0.65, and 0.90 represent low-, 159 
medium-, and high-separation conditions, respectively26. Posterior probabilities for drug profile 160 
membership were calculated for all residents in the cohort using the average parameter estimates 161 
from the five datasets. All residents were assigned to a specific drug profile based on modal 162 
assignment (the drug profile with the highest posterior probability). The distribution of sex and the 163 
  
median for age were performed for each drug profile. To account for local maxima of the likelihood 164 
function for LCA we initially used 450 randomly generated starting values. If the best likelihood 165 
were not replicated, then the number of starting values was increased. 166 
 167 
Ethics and reporting 168 
The study was approved by the Scientific Board of Statistics Denmark and the Danish Data 169 
Protection Agency (ref. 00003115). An approval from an ethics committee is not required for 170 
registry-based studies in Denmark. No identifiable patient data could be retrieved. The study was 171 
conducted by following the Strengthening the Reporting of Observational Studies in Epidemiology 172 
(STROBE) recommendations27.  173 
  
Results 174 
Drug use 175 
We identified 1,424,775 residents aged ≥60 years in Denmark in 2015. The female proportion was 176 
53%. The median age of the population was 70 years (interquartile range (IQR) 65-77, range 60 to 110) 177 
without differences across sex (70 years for men and 71 years for women). The most used single drug 178 
classes measured by the number of unique users were anilides (34%), statins (33%), platelet aggregation 179 
inhibitors (24%), proton pump inhibitors (21%), and calcium channel blockers (20%). (Table 1). 180 
 181 
Of all the older adults, 89% filled at least one prescription during 2015. The median number of unique 182 
drug classes filled was five per person (IQR, 2-8), similar for men and women (four drug classes (IQR, 183 
2-8) and five drug classes (IQR, 2-9), respectively). We observed a trend toward an increasing number 184 
of prescribed drug classes by age. However, with a levelling off around age 90 (Figure 1).  185 
 186 
Cardiovascular drugs were the most used main drug group (1≥ prescription filled by 62% of all 187 
residents), followed by drugs related to the nervous system (48%), alimentary tract and metabolism 188 
(38%), anti-infectives for systemic use (35%), and blood and blood-forming organs (34%). This was 189 
largely consistent across age (Figure 2), although with a tendency towards a slightly increased 190 
proportion of drugs related to blood and blood-forming organs was observed whereas the 191 
proportion of drugs related to the genitourinary system and sex hormones decreased slowly by age.  192 
 193 
Drug profiles 194 
By using the drugs from the 28 covering 95% of all drug groups used in 2015, we fitted up to a 20 195 
LCA class model. Looking at model fit, the BIC was lowest in the model with 19-drug profiles for 196 
four datasets and in the model with 18 drug profiles for one dataset. When comparing the 197 
therapeutic subgroup drug probabilities within each drug profile among the five different datasets 198 
for the 19-drug profile models, two of the 19-drug profiles were very differently estimated, showing 199 
no consistency among the datasets in how to identify them. However, for the 18-drug profile model, 200 
the results were similar (Appendix 1). Since no consistent pattern was obtained in the 19-drug 201 
profile model, and with a clinical judgment by a clinical difference in the drug profiles we used the 202 
18-drug profile model as our final model. Moreover, the mean entropy-based pseudo-R2 measure 203 
was in our study 0.67 (range: 0.66-0.68), placing the separation of the 18 drug profiles as medium-204 
separation conditions. 205 
 206 
  
Table 2 shows the conditional probabilities of the 28 therapeutic subgroup drugs in the 18 identified 207 
drug profiles and the relationship between age and sex for each drug profile. Multiple drug use was 208 
in this study defined as receiving drugs from five or more different therapeutic subgroup drugs. 209 
Multiple drug use was observed in 11 drug profiles (drug profile 1 to 11). Two of these drug profiles 210 
had a considerable overlap (drug profile 1 and 4). Thus, one drug profile (drug profile 1) consisted 211 
of high probabilities for all 28 therapeutic subgroup drugs and was characterised by the highest 212 
expected numbers of therapeutic subgroup drugs whereas the other drug profile (drug profile 4) had 213 
a high probability of receiving all therapeutic subgroup except for mineral supplements and 214 
diuretics. The second highest number of expected therapeutic subgroup drugs was observed in 215 
combination with the highest median age, and the highest proportion of females. The probability of 216 
receiving a drug for both the cardiovascular system, alimentary tract and metabolism, and for the 217 
blood and blood-forming organs were characterised for drug profile 1-7. An expected number of 218 
different therapeutic subgroup drugs under five were characterised for drug profile 12-18. The 219 
highest proportion of males was found in drug profile 12. Similar, drug profile 16 was characterised 220 
by low probability of receiving drugs except for hypertensive drugs. Drug profile 18 was the largest. 221 
It had a prevalence of 21% and consisted of those with a probability of zero or very close to zero 222 
for receiving any drug from the different included therapeutic subgroup drugs. The median age for 223 
residents in drug profile 18 was the lowest among the 18 drug profiles at 67 years old, and the sex 224 
ratio was also almost 1:1. Thus, the most prevalent drug profiles characterised by expected multiple 225 
drug use were drug profile 1-6 (11.2-7.6 expected therapeutic subgroup drugs) and had a total 226 
prevalence of 19%. To characterise the different therapeutic subgroup drugs used in LCA we have 227 
listed the three most frequent drug classes at the 28 different therapeutic subgroup drugs in 228 
Appendix 2.   229 
  
Discussion 230 
In this cross-sectional nationwide drug utilisation study, we investigated prescribing patterns and 231 
drug combination profiles in older adults in Denmark in 2015. Our study showed that extensive 232 
drug use among older adults was very common. Older people aged ≥60 years, redeemed drugs from 233 
five (median) different drug classes at the pharmacy each year. The number of redeemed drugs 234 
increased by age from a median level at 4 for persons between 60 and 69 years old to a median level 235 
at 8 for older people aged ≥80 years. However, the distribution of drugs from main groups was 236 
almost stable across age groups. Further, we identified 18 different drug profiles; one drug profile 237 
with a low probability of receiving any drugs, which included 21 % of the population ≥60, and 11 238 
drug profiles, which on average received drugs from more than five different therapeutic subgroups.  239 
 240 
Our study investigated current drug use among older adults in Denmark and showed that drug 241 
consumption is well within the range of previous studies. Previous studies were, however, primarily 242 
based on selected populations and fairly old data sets. To our knowledge, no other studies have 243 
included the entire Danish population ≥60 years. A Swedish study showed that older adults (≥65) used 244 
an average of 4.6 different drugs (ATC level 5)28 whereas, a Danish study found that the median 245 
number of drugs among residents ≥60 years was 5 (IQR: 2-9) (ATC level 5)29. We confirmed the 246 
findings from Linjakumpu et al.3 that the number of drugs increased by age. However, the increase in 247 
the number of redeemed drug classes seems larger in our study. One reason for this might be the larger 248 
population and the general increase in drug consumption. Similar to our findings, Lagerin et al.30 249 
reported that the number of drugs at ATC level 3 stabilised at the age of 85-90. This stabilisation of the 250 
drug use can be expected because the increased life expectancy in the older population has raised the 251 
prevalence of multi-morbidity31, and the number of drugs was highly correlated with the number of 252 
chronic conditions28. The impact of evidence-based clinical guidelines for the treatment of the specific 253 
disease may also contribute to the observed increase in drug use32. This can be explained by the fact 254 
that each guideline has several recommended drugs and the majority of older people are multimorbid. 255 
 256 
We found that cardiovascular drugs were the most commonly used main drug group, which is in 257 
accordance with previous findings. Barat et al. found that the two most common prescription drugs 258 
among 75-years-old community-dwelling residents were cardiovascular drugs (25%) and central 259 
nervous system drugs (23%)33. In a Swedish study among older adults ≥ 78 years of age, cardiovascular 260 
drugs were also the most frequently used drugs followed by nervous system drugs, and alimentary tract 261 
metabolism drugs32. Similar results were found by Wastesson et al.34. We further found that the 262 
  
distribution of main drug groups was stable over age, which indicates that the drug patterns do not 263 
change significantly with age and suggest that drugs may not be discontinued in late life. 264 
 265 
A complex drug burden is potentially harmful to the patients and difficult to manage10,35. The drug 266 
burden is often measured by the number of different drugs used but ignoring the complexity of the 267 
drug profiles. To our knowledge, LCA has never been performed in a large, national population, and 268 
with therapeutic subgroup drugs as outcomes. In previous studies, LCA has been used to define, e.g., 269 
subtypes of drug abuse in a Swedish cohort (n=192,501)36 and to identify patterns of drug use 270 
associated with lower serum sodium concentration in older hospitalised patients (n=101)37. In both 271 
studies, the drugs were selected to fit a selected patient group, and the analysis included only a limited 272 
number of drugs or drug classes, whereas only three and six different drug profiles were identified. In 273 
this study 18-drug profiles, i.e. clinical recognisable medication patterns were identified. For example, 274 
drug profile 13 is characterised by a high probability of receiving drugs for diabetes, agents acting on 275 
the renin-angiotensin system, and lipid-modifying agents. In general, the drug profiles demonstrated 276 
very complex therapeutic profiles and reflecting the high level of multimorbidity. However, the drug 277 
profiles should be explored more thoroughly to fit the clinical practice, e.g. to risk-stratified patients in 278 
a hospital or a general practice. When identifying drug profiles, LCA is considered highly suitable 279 
because the drug groups differ qualitatively from each other. Also, we found similar drug profiles for 280 
the five randomly selected samples which indicates that the 18 drug profiles are very stable. The drug 281 
profiles allow us to study drug use and drug combinations in a new way. By using the drug profiles, it is 282 
possible to identify in which of the drug profiles a given drug is used, and thereby restrict studies of 283 
adverse effects to individuals with different drug combination profiles. Real word evidence in different 284 
drug profiles makes the result more usable in clinical practice. We believe that the new method is 285 
important also when studying drug channelling bias in more sufficient ways, and when studying 286 
polypharmacy more comprehensively. 287 
 288 
Strengths and limitations 289 
Our study is the first study investigating drug profiles in a large population using LCA. The use of 290 
LCA in an unselected population enables a nuanced identification and description of drug profiles. 291 
More in-depth knowledge of the drug patterns is desired, e.g. studying drug profiles at drug class 292 
level instead of at therapeutic subgroup level. This was, however, not possible in this study due to 293 
the lack of computer power. In future studies, drug profiles have the potential to be evaluated on 294 
drug class level, to achieve knowledge on among other drug safety, interactions, adverse drug events, 295 
  
maybe by investigating individuals with a specific drug profile. Another strength of this study is that 296 
data were obtained from nationwide registers containing high-quality data. This ensures complete 297 
coverage and eliminates the risk of selection bias. 298 
 299 
A limitation of this study is that certain drugs can be purchased over the counter in Denmark and 300 
drug, therefore, can be slightly underestimated. Olesen et al.38 found that 28 percent of the patients 301 
aged 65 years or more used non-prescription drugs. Indeed, the majority are prescription drugs, 302 
especially with respect to the most potent drugs and those with the greatest potential of interactions. 303 
Another potential limitation is that we had no information on drug adherence among older adults. 304 
Though we know the older adults have filled the prescription, we do not know whether the older 305 
adults have taken the drug. At the same time, we eliminate primary non-adherence, which is a 306 
strength. We required at least one prescription for all drugs in the analyses, though we did not know 307 
if the older adults were compliant to the given drug. Due to the excessive computer running time, 308 
we were further compelled to reduce the population to five random samples of 50,000 individuals 309 
each. We assume a sample of 50,000 individuals as a large population, and that the results would not 310 
be different compared with the final population.  311 
 312 
In conclusion, we found that the use of drugs is extensive both at the population level and at the 313 
individual level and that it is increasing with age. Cardiovascular drugs, analgesics and psychotropic 314 
drugs were the most prevalent drug classes. Eighteen different drug profiles were identified, 11 drug 315 
profiles reflecting probable drug combination profiles among users of multiple drug use. The 316 
identified drug profiles described clinical recognisable medication patterns. The drug profiles have 317 
the potential to be used in future studies investigating high-risk prescriptions patterns. Studies of the 318 
older adult population with diverging drug profiles may provide useful information to prevent drug-319 
related problems and optimise drug treatment. For instance, with more research into risk patterns, 320 
we can produce risk profiles that will provide a better understanding of which patients benefit most 321 
from medication review. Furthermore, these risk profiles may also benefit the patients when a new 322 
medication is added to the treatment for a more rational drug prescribing.  323 
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Figure 1: Number of unique drug classes depicted as a function of age.  2 
Boxes represent the interquartile range with the median score shown as a horizontal line and the 3 





Figure 2 Parts a-b: Overall distribution of drugs used.  4 




Table 1. Demographic and drug characteristics. 1 










 1424775 688623 (48.3) 490295 (34.4) 245857 (17.3) 
Sociodemographic characteristics     
Female sex 759255 (53.3) 348609 (50.6) 258311 (52.7) 152335 (62.0) 
Marital status     
Marrieda  842138 (59.1) 456828 (66.3) 300875 (61.4) 84435 (34.3) 
Widowed 274533 (19.3) 48189 (7.0) 96843 (19.75) 129501 (52.7) 
Divorced 201153 (14.1) 112102 (16.3) 68038 (13.9) 21013 (8.6) 
Single 106951 (7.5) 71504 (10.4) 24539 (5.0) 10908 (4.4) 
Highest achieved educationb     
Short (7-10 years) 498173 (36.0) 185095 (27.4) 186750 (39.2) 126328 (54.9) 
Medium (11–12 years) 551070 (39.9) 294205 (43.6) 188201 (39.5) 68664 (29.8) 
Long (≥13 years) 333118 (24.1) 195837 (29.0) 102088 (21.4) 35193 (15.3) 
Medication     
Median number drug classes (IQRc)  5 (2-8) 4 (1-7) 5 (3-9) 8 (4-11) 
Number of simultaneously used drugs classes     
0 155,692 (10.9) 105,130 (15.3) 40,986 (8.4) 9,576 (3.9) 
1-2 253,138 (17.8) 157,282 (22.8) 76,033 (15.5) 19,823 (8.1) 
3-4 264,930 (18.6) 141,372 (20.5) 90,590 (18.5) 32,968 (13.4) 
5-9 477,536 (33.5) 201,525 (29.3) 178,395 (36.4) 97,616 (39.7) 
10+ 273,479 (19.2) 83,314 (12.1) 104,291 (21.3) 85,874 (34.9) 
10 most frequent drugs classes     
Anilids ((N02BE) 483,772 (34.0)  184,981 (26.9) 173,338 (35.4) 125,453 (51.0) 
HMG CoA reductase inhibitors (C10AA)  466,062 (32.7) 190,265 (27.6) 189,804 (38.7) 85,993 (35.0) 
Platelet aggregation inhibitors excl. heparin 
(B01AC) 337,985 (23.7) 109,735 (15.9) 134,318 (27.4) 93,932 (38.2) 
Proton pump inhibitors (A02BC) 295,668 (20.8) 120,132 (17.4) 108,428 (22.1) 67,108 (27.3) 
Dihydropyridine derivatives (C08CA) 285,250 (20.0) 107,662 (15.6) 110,412 (22.5) 67,176 (27.3) 
Beta blocking agents, selective (C07AB) 241,009 (16.9) 82,228 (11.9) 94,658 (19.3) 64,123 (26.1) 
Propionic acid derivatives (M01AE) 229,475 (16.1) 120,989 (17.6) 78,864 (16.1) 29,622 (12.0) 
ACE inhibitors, plain (C09AA) 206,732 (14.5) 80,935 (11.8) 79,301 (16.2) 46,496 (18.9) 
Beta-lactamase sensitive penicillins (J01CE) 199,701 (14.0) 94,581 (13.7) 67,817 (13.8) 37,303 (15.2) 
Thiazides and potassium in combination (C03AB) 185,262 (13.0) 65,308 (9.5) 71,188 (14.5) 48,766 (19.8) 
     
a Includes registered partnership 2 
b Missing: 42,414 people 3 
c IQR= interquartile range 4 
  
 1 
Table 1: The conditional probabilities of the 28 therapeutic subgroup drugs in the 18 identified drug profiles.  2 
Profile Pa 1 2 3 4 5 6 7 8 
Profile size, No (%)  42,743 (3) 28,496 (2) 56,991 (4) 56,991 (4) 42,743 (3) 42,743 (3) 71,239 (5) 42,743 (3) 
Age, median (IQR) 70 (62-77) 78 (71-84) 81 (72-89) 78 (71-84) 75 (69-82) 75 (68-82) 71 (66-77) 72 (68-78) 73 (66-81) 
Sex, female (%) 53.3 62.5 72.7 48.7 49.7 61.1 68.6 36.1 74.9 
Expected number of therapeutic subgroup drugs  11.2 8.3 8.1 7.6 7.6 7.2 6.7 6.7 
Therapeutic subgroup drug          
A02: Drugs for acid related disorders 22% 72% 60% 30% 49% 45% 43%  20% 62% 
A06: Drugs for constipation 5% 29% 43%  6% 12% 22%  2%  1% 25% 
A10: Drugs used in diabetes 11% 34%  5%  20% 16% 28%  11% 55%  2% 
A12: Mineral supplement 10% 63% 74% 59% 0% 16%  8%  18%  2% 
B01: Antithrombotic agents 30% 90% 43% 99% 100% 62%  28% 77%  17% 
B03: Antianemic preparations 6% 25% 22%  9% 13% 17%  5%  11%  14% 
C01: Cardiac Therapy 6% 38%  12% 46% 33% 3%  3%  8%  2% 
C03: Diuretics 23% 91% 91% 96% 12% 36% 37% 48%  18% 
C07: Beta blocking agents 20% 59%  22% 81% 55%  25%  21% 55%  10% 
C08: Calcium channels blockers 21% 41%  24% 33% 33% 39% 32% 62%  12% 
C09: Agents acting on the renin-angiotensin system 36% 60%  27% 66% 47% 62% 59% 96%  20% 
C10: Lipid modifying agents 33% 76%  15%  64% 73% 73% 45% 91%  16% 
D07: Topical dermatological Corticosteroids 13% 26%  22%  15% 21%  16% 35%  13% 23% 
G03: Sex hormones and modulators of the genital system 10% 17%  14%  6% 13%  10% 26%  3% 26% 
G04: Urologicals 10% 16%  11%  13% 18%  14%  12%  14%  11% 
H02: Corticosteroids for system use 6% 27% 19%  8% 12%  0% 19%  2% 17% 
H03: Thyroid therapy 6% 14%  12%  10% 8%  11%  10%  5%  11% 
M01: Antiinflammatory and antirheumatic products 19% 25%  23%  10% 24%  19% 32%  11% 46% 
M05: Drugs for treatment of bone diseases 6% 16% 19%  6% 11%  8%  8%  1% 16% 
N02: Analgesics 38% 94% 89% 53% 76% 73% 63%  31% 97% 
N03: Antiepileptics 5% 20% 17%  3% 10% 20%  4%  3% 23% 
N04: Anti-parkinson drugs 2% 6% 6%  1% 3% 7%  2%  0% 7% 
N05: Psycholeptics 15% 45% 42%  16% 30% 46% 28%  6% 55% 
N06: Psychoanaleptics 13% 40% 44%  11% 22% 61%  15%  8% 48% 
R01: Nasal preparations 6% 11%  5%  4% 9%  2% 41%  3%  13% 
R03: Drugs for obstructive airways diseases 13% 41% 29%  19% 22%  13% 43%  7% 25% 
R06: Antihistamines for systemic use 6% 17%  12%  4% 11%  6% 43%  3% 19% 
S01: Ophthalmologicals 17% 31% 29%  18% 26%  23% 48%  17% 31% 
          
  
Profile 9 10 11 12 13 14 15 16 17 18 
Profile size, N (%) 71239 (5) 28,496 (2) 71,239 (5) 113,982 (8) 56,991 (4) 1,245 (0.1) 128,230 (9) 156,725 (11) 99,734 (7) 299,203 (21) 
Age, median (IQR) 71 (66-77) 74 (68-81) 74 (68-82) 72 (68-79) 70 (65-75) 69 (64-75) 68 (64-74) 70 (65-75) 69 (64-74) 67 (63-72) 
Sex, female (%) 55.1 69.2 75.3 34.7 39.0 63.8 60.8 50.2 62.7 49.0 
Expected number of therapeutic Subgroup drugs 6.4 5.2 5.1 4.3 4.2 3.3 3.0 2.9 2.8 0.5 
Therapeutic subgroup drug           
A02: Drugs for acid related disorders 41% 33%  18%  13%  14%  17%  25%  10%  18%  3% 
A06: Drugs for constipation  4%  5%  2%  0%  1%  7%  3%  0%  1%  0% 
A10: Drugs used in diabetes  18%  4%  7%  3% 56%  2%  1%  3%  1%  1% 
A12: Mineral supplement  7%  7% 41%  1%  0%  0%  0%  4%  0%  0% 
B01: Antithrombotic agents  35%  30%  24% 97%  34%  10%  3%  7%  4%  1% 
B03: Antianemic preparations  6% 16%  6%  3%  8%  7%  4%  2%  4%  1% 
C01: Cardiac Therapy  1%  1%  1%  13%  0%  1%  0%  1%  1%  0% 
C03: Diuretics  32%  20% 100%  12%  8%  6%  5%  21%  4%  1% 
C07: Beta blocking agents  23%  10% 30% 47%  4%  8%  3%  17%  2%  1% 
C08: Calcium channels blockers 43%  23% 33%  25%  21%  8%  4% 43%  4%  1% 
C09: Agents acting on the renin-angiotensin system 72%  33%  43%  42% 69%  14%  11% 68%  10%  4% 
C10: Lipid modifying agents 55%  28%  31% 66% 85%  16%  7%  28%  11%  4% 
D07: Topical dermatological Corticosteroids  14%  8%  15%  10%  10%  12%  11%  10%  22%  5% 
G03: Sex hormones and modulators of the genital system  12%  11%  14%  4%  4%  15%  13%  7%  19%  5% 
G04: Urologicals  14%  7%  4%  14%  14%  7%  9%  10%  10%  4% 
H02: Corticosteroids for system use  6% 52%  4%  2%  2%  1%  5%  1%  10%  0% 
H03: Thyroid therapy  6%  10%  12%  4%  6%  9%  4%  4%  7%  2% 
M01: Antiinflammatory and antirheumatic products 71%  18%  16%  7%  14%  8%  58%  9%  10%  4% 
M05: Drugs for treatment of bone diseases  4% 43%  7%  3%  2%  7%  6%  3%  8%  2% 
N02: Analgesics 100% 60%  42%  20%  22%  35% 78%  13%  17%  3% 
N03: Antiepileptics  7%  3%  2%  2%  1%  11%  3%  1%  1%  0% 
N04: Anti-parkinson drugs  2%  2%  1%  1%  1%  5%  1%  0%  0%  0% 
N05: Psycholeptics  18%  14%  12%  5%  5% 46%  10%  5%  9%  1% 
N06: Psychoanaleptics  9%  15%  8%  5%  7% 45%  5%  4%  5%  1% 
R01: Nasal preparations  5%  0%  2%  4%  3%  2%  4%  3% 23%  1% 
R03: Drugs for obstructive airways diseases  11% 44%  12%  7%  7%  7%  9%  6% 26%  2% 
R06: Antihistamines for systemic use  5%  0%  4%  2%  3%  3%  3%  2% 18%  0% 
S01: Ophthalmologicals  16%  19%  18%  13%  14%  16%  12%  12% 30%  7% 
a=probability of receiving the therapeutic subgroup drug in general 3 
Bold: 25% Increase of the overall probability. The colored boxes: Increase of at least 10 percent points over the overall probability. Different colors represent 4 
different main groups 5 
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Figure 3. 18 drug profile model. Five datasets with 50,000 individuals for each class. 8 
  
Appendix 2:  1 
Supplement to: Use of prescription drugs in the older adult population – a nationwide pharmacoepidemiological 2 
study. Christensen LD*, Reilev M, Juul-Larsen HG, Jørgensen LM, Kaae S, Andersen O, Pottegård A, Petersen J. 3 
*Corresponding author: Clinical Research Center, Copenhagen University Hospital Hvidovre, Denmark, Kettegaard 4 
Allé 30, 2650 Hvidovre, Denmark. E-mail: Line.due.christensen@regionh.dk or linedue@gmail.com, phone: (+45) 5 
38623350 6 
 7 
Table 3. Three most frequent drug classes in the 28 therapeutic subgroup drugs used for the Latent Class Analysis 8 
Therapeutic subgroup drugs  Drug classes 
A02: Drugs for acid related disorders A02BC: proton pump inhibitors, A02AA: magnesium compounds, A02AD: combinations 
and complexes of aluminium, calcium and magnesium compounds 
A06: Drugs for constipation A06AD: Osmotically acting laxatives, A06AB: Contact laxatives, A06AG: Enemas 
A10: Drugs used in diabetes A10BA: Biguanides, A10BB: Sulfonylureas, A10AE: Insulins and analogues for injection, 
long-acting 
A12: Mineral supplement A12BA: Potassium, A12AA: Calcium, A12AX: Calcium, combinations with vitamin D 
and/or other drugs 
B01: Antithrombotic agents B01AC: Platelet aggregation inhibitors excl. heparin, B01AA: Vitamin K antagonists, 
B01AF: Direct factor Xa inhibitors 
B03: Antianemic preparations B03BA: Vitamin B12 (cyanocobalamin and analogues), B03BB: Folic acid and derivatives, 
B03AA: Iron bivalent, oral preparations 
C01: Cardiac Therapy C01DA: Organic nitrates, C01AA: Digitalis glycosides, C01BD: Antiarrhythmics, class III 
C03: Diuretics C03AB: Thiazides and potassium in combination, C03CA: Sulfonamides, plain, C03DA: 
Aldosterone antagonists 
C07: Beta blocking agents C07AB: Beta blocking agents, selective, C07AG: Alpha and beta blocking agents, C07AA: 
Beta blocking agents, non-selective 
C08: Calcium channels blockers C08CA: Dihydropyridine derivatives, C08DA: Phenylalkylamine derivatives, C08DB: 
Benzothiazepine derivatives 
C09: Agents acting on the renin-angiotensin system C09AA: ACE inhibitors, plain, C09CA: Angiotensin II antagonists, plain, C09DA: 
Angiotensin II antagonists and diuretics 
C10: Lipid modifying agents C10AA: HMG CoA reductase inhibitors, C10AX: Other lipid modifying agents, C10AB: 
Fibrates 
D07: Topical dermatological Corticosteroids D07AC: Corticosteroids, potent (group III), D07AB: Corticosteroids, moderately potent 
(group II), D07AD: Corticosteroids, very potent (group IV) 
G03: Sex hormones and modulators of the genital system G03CA: Natural and semisynthetic estrogens, plain, G03FA: Progestogens and estrogens, 
fixed combinations, G03FB: Progestogens and estrogens, sequential preparations 
G04: Urologicals G04BE: Drugs used in erectile dysfunction, G04CA: Alpha-adrenoreceptor antagonists, 
G04BD: Drugs for urinary frequency and incontinence 
H02: Corticosteroids for system usea
 
H02AB: Glucocorticoids, H02AA: Mineralocorticoids 
H03: Thyroid therapy H03AA: Thyroid hormones, H03BB: Sulfur-containing imidazole derivatives, H03BA: 
Thiouracils 
M01: Antiinflammatory and antirheumatic products M01AE: Propionic acid derivatives, M01AB: Acetic acid derivatives and related substances, 
M01AX: Other antiinflammatory and antirheumatic agents, non-steroids 
M05: Drugs for treatment of bone diseases M05BA: Bisphosphonates, M05BX: Other drugs affecting bone structure and 
mineralization, M05BB: Bisphosphonates, combinations 
N02: Analgesics N02BE: Anilids, N02AX: Other opioids, N02AA: Natural opium alkaloids 
N03: Antiepileptics N03AX: Other antiepileptics, N03AF: Carboxamide derivatives, N03AG: Fatty acid 
derivatives 
N04: Anti-parkinson drugs N04BC: Dopamine agonists, N04BA: Dopa and dopa derivatives, N04BD: Monoamine 
oxidase B inhibitors 
N05: Psycholeptics N05CF: Benzodiazepine related drugs, N05BA: Benzodiazepine derivatives , N05AH: 
Diazepines, oxazepines, thiazepines and oxepines 
N06: Psychoanaleptics N06AA: Non-selective monoamine reuptake inhibitors, N06AB: Selective serotonin 
reuptake inhibitors, N06AX: Other antidepressants  
R01: Nasal preparations R01AD: Corticosteroids, R01AX: Other nasal preparations, R01AA: Sympathomimetics, 
plain 
R03: Drugs for obstructive airways diseases R03AC: Selective beta-2-adrenoreceptor agonists, R03AK: Adrenergics in combination 
with corticosteroids or other drugs, excl. anticholinergics, R03BB: Anticholinergics 
R06: Antihistamines for systemic use R06AX: Other antihistamines for systemic use, R06AE: Piperazine derivatives, R06AD: 
Phenothiazine derivatives 
S01: Ophthalmologicals S01AA: Antibiotics, S01XA: Other ophthalmologicals, S01CA: Corticosteroids and 
antiinfectives in combination 
  
a Only two drug classes  9 
